AmmPower Corp. Announces Board and Management Changes 11-02-2023, 07:29

Io Therapeutics, Inc., presented today results from studies of IRX4204, the company’s phase II clinical development stage, highly selective RXR nuclear receptor agonist compound, supporting its potential use for treatment of amyotrophic lateral sclerosis 16-07-2024, 20:26

nCino to Participate in Upcoming Investor Events 22-11-2023, 04:05